383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)

Autor:	F. de Braud, Filippo Pagani, Lorenzo Antonuzzo, C. Cagnazzo, Massimo Milione, Federica Palermo, Giuliana Ritorto, Margherita Ratti, Federica Morano, Nicoletta Pella, Michele Prisciandaro, Filippo Pietrantonio, S. Lonardi, Alessandra Raimondi, M. Di Bartolomeo, Sabina Murgioni, Iolanda Capone, A. Zaniboni, Federica Marmorino, Lisa Salvatore
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty Temozolomide business.industry Colorectal cancer Low dose Priming (immunology) Ipilimumab Hematology medicine.disease Microsatellite Stable Internal medicine Medicine In patient Nivolumab business medicine.drug
Zdroj:	Annals of Oncology. 32:S530-S531
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.905
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ffe3b47ebd928dbd6474dce043f5a69f https://doi.org/10.1016/j.annonc.2021.08.905 Zobrazit plný text záznamu